- জেনেরিক নাম
- Rifampicin
- শক্তি
- 450 mg
- ডোজ ফর্ম
- Capsule
- প্রস্তুতকারক
- National Laboratories Ltd.
Rimpacin Capsule
Rimpacin 450 mg Capsule সম্পর্কে
Rimpacin 450 mg Capsule একটি ক্যাপসুল ঔষধ, যার জেনেরিক নাম Rifampicin এবং শক্তি ৪৫০ mg। Rimpacin-এর সাথে Rifampicin-এর অন্য ব্র্যান্ডের দাম নিচে তুলনা করে দেখুন। Rimpacin প্রস্তুত করেছে National Laboratories Ltd। ডাক্তারের প্রেসক্রিপশন মেনে চলুন এবং অন্য ব্র্যান্ড খাওয়া যাবে কি না তা ফার্মাসিস্টের কাছ থেকে জেনে নিন।
Rifampicin-এর ১৮টি ব্র্যান্ড বাংলাদেশে তালিকাভুক্ত। সবচেয়ে কম দাম Firifam 150 mg Tablet-এর, প্রতি ইউনিট ৳ ১।
Rimpacin 450 mg Capsule কী?
Rimpacin 450 mg is a capsule form of rifampicin, an anti-tubercular antibiotic that works by blocking RNA transcription in bacteria. It is used for tuberculosis and to treat meningococcal carriers. Because bacteria can become resistant quickly, it is given as part of a combination regimen chosen by a doctor. Laboratory tests are usually done before treatment starts to confirm the bacteria are susceptible. The doctor decides the dose and course.
Rimpacin-এর ব্যবহার
Rimpacin is used in the treatment of tuberculosis and in people who carry meningococcal bacteria. For tuberculosis, it is combined with other medicines as part of a full treatment plan. It is not used alone for tuberculosis because resistance can develop. Your doctor will decide whether it is suitable for your condition and how long you need it.
Rimpacin কীভাবে ব্যবহার করবেন
Take Rimpacin capsules exactly as your doctor tells you. Swallow with a full glass of water. The doctor will decide the dose, timing and length of treatment. Do not skip doses or stop early, even if you feel better, as this can make the infection harder to treat. If you miss a dose, ask your doctor or pharmacist what to do. Keep all appointments for tests.
Rimpacin-এর পার্শ্বপ্রতিক্রিয়া
Common side effects include facial flushing and itching, nausea, vomiting, diarrhoea and stomach upset. Body fluids such as urine, sweat, saliva and tears may turn orange-red; this is expected and usually harmless. Tell your doctor if you have fever, chills, headache, dizziness, bone pain, shortness of breath, unusual tiredness, yellowing of the eyes or skin, or changes in urine output. Seek medical help for severe reactions.
সতর্কতা ও নিরাপত্তা
Tell your doctor before starting Rimpacin if you have liver disease, kidney problems, or are allergic to rifamycins. It can affect how other medicines work, so give your doctor a full list of your medicines. In pregnancy, especially near delivery, it may cause bleeding problems in mother and baby; breastfeeding decisions need medical advice. Do not start or stop this medicine without your doctor's guidance. Your doctor will decide if monitoring tests are needed.
সাধারণ প্রশ্ন
Is Rimpacin safe to use during pregnancy or breastfeeding?
Rifampicin may cause bleeding problems in the mother and baby when used near the end of pregnancy. During breastfeeding, the decision to continue needs medical advice. Talk to your doctor before using Rimpacin if you are pregnant, planning pregnancy or breastfeeding; they will decide what is suitable for you.
What is Rimpacin used for and what kind of medicine is it?
Rimpacin contains rifampicin, an antibiotic used to treat tuberculosis and to clear meningococcal bacteria in carriers. It works by stopping bacteria from making RNA. It is usually given with other medicines for tuberculosis. Your doctor will decide the right combination and course for your condition.
What side effects should I watch for and when should I call the doctor?
Watch for nausea, vomiting, diarrhoea, itching, or orange-red body fluids. Call your doctor if you have fever, chills, headache, dizziness, bone pain, shortness of breath, unusual tiredness, yellowing of eyes or skin, or reduced urine. Severe reactions need urgent medical attention.
Can I stop taking Rimpacin when I feel better?
No. Stopping early or skipping doses can let bacteria survive and become resistant, making treatment harder. Always follow your doctor's instructions about how long to take it. If you have side effects or miss a dose, ask your doctor or pharmacist for advice rather than changing the plan yourself.
নির্দেশনা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the ... Read moreIn the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampinand they should be repeated throughout therapy to monitor the response to treatment. Since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. If test results show resistance to rifampin and the patient is not responding to therapy, the drug regimen should be modified.ফার্মাকোলজি
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Rifampicin suppresses initiation of chain formation for RNA synthesis in susceptible bacteria by binding to the β subunit of DNA-dependent RNA polymerase, thus blocking RNA transcription.মাত্রা ও সেবনবিধি
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Rifampin can be administered by the oral route or by IV infusion. IV doses are the same as those for oral.Tuberculosis:
- Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, oral or IV
- Pediatric Patients: 10–20 mg/kg, not to exceed 600 mg/day, oral or IV
Rifampin is indicated in the treatment of all forms of tuberculosis. A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide is recommended in the initial phase of shortcourse therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.
Following the initial phase, treatment should be continued with rifampin and isoniazid for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.
ঔষধের মিথষ্ক্রিয়া
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
May accelerate the metabolism and reduce the effect of drugs that are metabolised by CYP450 enzymes (e.g. quinidine, phenytoin, theophylline). Decreased concentrations of atovaquone and increased concentrations of rifampicin when taken concomitantly. Concurrent use of ketoconazole and rifampicin may result in decreased serum concentrations of both drugs. May decrease serum concentrations of enalaprilat. Reduced absorption by antacids. Increased risk of hepatotoxicity with halothane or isoniazid.প্রতিনির্দেশনা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Rifampicin is contraindicated in patients with a history of hypersensitivity to rifampin or any of the components, or to any of the rifamycins. Rifampin is contraindicated in patients who are also receiving ritonavir-boosted saquinavir due to an increased risk of severe hepatocellular toxicity.Rifampin is contraindicated in patients who are also receiving atazanavir, darunavir, fosamprenavir, saquinavir, or tipranavir due to the potential of rifampin to substantially decrease plasma concentrations of these antiviral drugs, which may result in loss of antiviral efficacy and/or development of viral resistance.
পার্শ্ব প্রতিক্রিয়া
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Facial flushing and itching, with or without a rash, flu-like syndrome characterised by episodes of fever, chills, headache, dizziness, bone pain, shortness of breath, and malaise; GI adverse effects (e.g. nausea, vomiting, anorexia, diarrhoea, epigastric distress), pseudomembranous colitis, eosinophilia, leucopenia, haemolytic anaemia; alterations in kidney function and renal failure, menstrual disturbances, oedema, myopathy, muscular weakness; orange-red discolouration of the urine, faeces, sweat, saliva, sputum, tears, and other body fluids; thrombophlebitis, local irritation and inflammation after prolonged IV infusion. Rarely, eye irritation and visual disturbances, anaphylaxis or shock.গর্ভাবস্থায় ও স্তন্যদানকালে
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Pregnancy: When administered during the last few weeks of pregnancy, rifampin can cause post natal hemorrhages in the mother and infant for which treatment with vitamin K may be indicated.Nursing Mothers: Because of the potential for tumorigenicity shown for rifampin in animal studies, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
সতর্কতা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Rifampicin has been shown to produce liver dysfunction. Fatalities associated with jaundice have occurred in patients with liver disease and in patients taking rifampin with other hepatotoxic agents. Patients with impaired liver function should be given rifampin only in cases of necessity and then with caution and under strict medical supervision. In these patients, careful monitoring of liver function, especially SGPT/ALT and SGOT/AST should be carried out prior to therapy and then every 2 to 4 weeks during therapy. If signs of hepatocellular damage occur, rifampin should be withdrawn.In some cases, hyperbilirubinemia resulting from competition between rifampin and bilirubin for excretory pathways of the liver at the cell level can occur in the early days of treatment. An isolated report showing a moderate rise in bilirubin and/or transaminase level is not in itself an indication for interrupting treatment; rather, the decision should be made after repeating the tests, noting trends in the levels, and considering them in conjunction with the patient's clinical condition.
Rifampin has enzyme-inducing properties, including induction of delta amino levulinic acid synthetase. Isolated reports have associated porphyria exacerbation with rifampin administration.
মাত্রাধিক্যতা
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Nausea, vomiting, abdominal pain, pruritus, headache, and increasing lethargy will probably occur within a short time after ingestion; unconsciousness may occur when there is severe hepatic disease. Transient increases in liver enzymes and/or bilirubin may occur. Brownish-red or orange discoloration of the skin, urine, sweat, saliva, tears, and feces will occur, and its intensity is proportional to the amount ingested.Liver enlargement, possibly with tenderness, can develop within a few hours after severe overdosage; bilirubin levels may increase and jaundice may develop rapidly. Hepatic involvement may be more marked in patients with prior impairment of hepatic function. Other physical findings remain essentially normal. A direct effect upon the hematopoietic system, electrolyte levels, or acid-base balance is unlikely.
Facial or periorbital edema has also been reported in pediatric patients. Hypotension, sinus tachycardia, ventricular arrhythmias, seizures and cardiac arrest were reported in some fatal cases.
সংরক্ষণ
এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।
Store between 15-30° C. Avoid excessive heat and protect from light.বিকল্প ব্র্যান্ড: Rifampicin
একই জেনেরিকের অন্য ব্র্যান্ড, কম দাম আগে।
ঔষধের তথ্য শুধু জানার জন্য, এটি চিকিৎসা পরামর্শ নয়। সবসময় ডাক্তারের প্রেসক্রিপশন মানুন এবং ফার্মাসিস্টের সাথে কথা বলুন।